BryoLogyx has completed the synthesis of bryostatin-1 molecule, pursuant to FDA’s Good Manufacturing Practice (GMP) regulations. Bryostatin-1 is the company’s lead compound being developed to improve patient outcomes by amplifying the response and increasing the durability of targeted cancer immunotherapies.   The GMP synthesis, accomplished in partnership with Albany Molecular Research Inc. (AMRI), a global contract research, development and manufacturing organization (CDMO), paves the way for ...